Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.

Ann Rheum Dis 2015 Aug 1;74(8):1530-6. Epub 2014 Apr 1.

Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, Ontario, Canada.

Background: The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE.

Methods: Recently diagnosed (<15 months) patients with SLE from 30 centres across 11 countries were enrolled into the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort from 2000 onwards. Baseline and annual assessments recorded clinical, laboratory and therapeutic data. A longitudinal analysis of factors associated with MetS in the first 2 years of follow-up was performed using random effects logistic regression.

Results: We studied 1150 patients with a mean (SD) age of 34.9 (13.6) years and disease duration at enrolment of 24.2 (18.0) weeks. In those with complete data, MetS prevalence was 38.2% at enrolment, 34.8% at year 1 and 35.4% at year 2. In a multivariable random effects model that included data from all visits, prior MetS status, baseline renal disease, SLICC Damage Index >1, higher disease activity, increasing age and Hispanic or Black African race/ethnicity were independently associated with MetS over the first 2 years of follow-up in the cohort.

Conclusions: MetS is a persistent phenotype in a significant proportion of patients with SLE. Renal lupus, active inflammatory disease and damage are SLE-related factors that drive MetS development while antimalarial agents appear to be protective from early in the disease course.

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2013-203933DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515988PMC
August 2015
106 Reads

Publication Analysis

Top Keywords

systemic lupus
8
lupus erythematosus
8
metabolic syndrome
8
disease activity
8
early disease
8
disease
6
mets
5
mets development
4
independently associated
4
phenotype corticosteroid
4
corticosteroid exposure
4
exposure time
4
race/ethnicity independently
4
disease phenotype
4
associated mets
4
development antimalarial
4
mets disease
4
association mets
4
lupus active
4
patients sle
4

References

(Supplied by CrossRef)
Lupus Atherosclerosis Prevention Study (LAPS)
Petri et al.
Ann Rheum Dis 2011
The metabolic syndrome
Cornier et al.
Endocr Rev 2008
The metabolic syndrome in systemic lupus erythematosus
Parker et al.
Rheum Dis Clin North Am 2010

Similar Publications